Artificial Intelligence and Biotechnology

Following the recent excitement surrounding technologies such as CAR-T therapy and CRISPR, the focus on targeted therapeutics looks set to progress in 2020.

This year is likely to witness a continued drive towards personalised medicine within the pharmaceutical and biotech sectors, together with an increased focus on developing the data capture and analytics capabilities necessary for these new therapies to realise their full potential.

To maximise impact across areas such as drug discovery, diagnostics, patient selection and treatment optimisation, there is a growing interest in new ways of acquiring and analysing patient data.

Recent developments in fields such as AI and machine learning are also playing an increasingly influential role in the biotech space, with FDA approvals of AI algorithms increasing exponentially over the past few years, and the AI healthcare market predicted to reach $6.6 billion by 2021. This article provides a detailed overview of the key developments taking place.